Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Disease;Neurological
Interventions: MR Fingerprinting; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pain
Interventions: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg, Palbociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Literacy, Communication, Nonverbal
Interventions: ALLSTAR; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: State College, Pennsylvania

Conditions: Acute Respiratory Failure
Interventions: Rapid sequence intubation: sedative first, Rapid sequence intubation: paralytic first; Other
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Age-related Cognitive Decline
Interventions: MRI; Device
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 45 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy Volunteers
Interventions: LOXO-305, Omeprazole; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip, Osteo Arthritis Shoulders, Synovitis of Knee, Synovitis/Tenosynovitis - Hip, Synovitis, Pain, Chronic
Interventions: Shoulder/Hip/Knee Embolization with Embozene Microspheres; Device
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 25 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Medullary Thyroid Cancer (MTC)
Interventions: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]; Biological
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy
Interventions: Investigational Medicinal Product (MR1), Investigational Medicinal Product (MR2), Investigational Medicinal Product (MR3), Investigational Medicinal Product (MR4), Investigational Medicinal Product (MR5), Investigational Medicinal Product (IR); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hyperkalemia
Interventions: LOKELMA 5 GM Powder for Oral Suspension; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more

Conditions: Cognition Disorders, Brain Pathology, Physical Disability, Physical Activity, Aging
Interventions: Aerobic Activity, Resistance Training, Yoga, Health Education; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Growth Hormone Deficiency With Pituitary Anomalies
Interventions: Macimorelin, Insulin; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Torrance, California • Austin, Texas • Houston, Texas + 1 more

Conditions: Methamphetamine-dependence, Substance Abuse
Interventions: Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Torrance, California

Conditions: MTBI - Mild Traumatic Brain Injury
Interventions: PATH + DigitMemory (DM) neurotraining; Behavioral
Lead sponsor: Perception Dynamics Institute; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: San Diego, California • Solana Beach, California

Conditions: Caregivers of People Living With Dementia, Dementia
Interventions: Cognitive Empathy Training, Control Condition, Pre and post intervention blood spot collection, Pre and post intervention MRI session; Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: High Grade Sarcoma
Interventions: Intensity Modulated Radiation Therapy (IMRT), MRI; Radiation · Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stroke, Ischemic Stroke, Cerebrovascular Disease
Interventions: Clinical scenarios; Other
Lead sponsor: Unity Health Toronto; Other
Eligibility: 20 Years to 75 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Interventions: ONO-9054, Placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 3
States / cities: Costa Mesa, California • Newport Beach, California • Santa Ana, California

Conditions: Healthy
Interventions: Lu AG06466, Itraconazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alcohol Drinking
Interventions: Motivational Interviewing, Culturally Tailored MI; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients
Interventions: cardiac MRI with DWI; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Harrison, New York • New York, New York

Search by objective public record fields.

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

MR Fingerprinting: A Novel Sequence Applied to Neuroimaging

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

Enhancing Orthographic Communication and Literacy Outcomes for AAC Learners

Drug Order for Rapid Sequence Intubation

Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Safety Interaction Trial Ibudilast and Methamphetamine

Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain Injury

Effect of Cognitive Empathy Training on Dementia Caregivers

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Clinician JUdgment Versus Risk Score to Predict Stroke outComes: The JURASSIC Clinical Trial

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

A Randomized Clinical Trial of Culturally Tailored MI

Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity